Latest news
18.02.2019
DEINOVE announces its financial calendar for 2019
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
31.01.2019
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner
The test design has been improved for a better assessment of DNV3837 effectiveness in treating Clostridium difficile infections, This will...
10.01.2019
A new website to highlight DEINOVE’s disruptive innovation strategy
The new DEINOVE website displays an updated presentation of DEINOVE’s corporate activities and identity It illustrates the disruptive...
Press Coverage
01.02.2019
La Tribune | La biotech Deinove entre en phase clinique sur un antibiotique novateur
Lire l'article
10.10.2018
La Biotech.eu | How to Make Industrial Biotech Pay
Making enough money to survive long enough to get a product to market can be tough for any biotech, but even more so for companies...
10.10.2018
Le Revenu : Emmanuel Petiot «Deinove pourrait avoir commercialisé six actifs d’ici fin 2019»
Recentré sur les secteurs de la chimie de spécialité et des antibiotiques, la biotech industrielle a récemment signé des accords pour...